Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03271710
Other study ID # CSP1121
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date September 1, 2017
Est. completion date December 30, 2018

Study information

Verified date July 2019
Source Contego Medical, LLC
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The ENTRAP Study is a prospective, multi-center, non-randomized, single-arm, study with follow-up to 30 days to determine the acute safety, acute device performance and clinical performance of the Vanguard IEP Peripheral Balloon Angioplasty System with Integrated Embolic Protection. The Vanguard IEP Peripheral Balloon Angioplasty System with Integrated Embolic Protection is indicated for peripheral vascular percutaneous transluminal angioplasty (PTA) and capture and removal of embolic material during angioplasty for the femoral, iliac, popliteal and profunda arteries.


Description:

The ENTRAP Study is a prospective, multi-center, non-randomized, single-arm, study with follow-up to 30 days to determine the acute safety, acute device performance and clinical performance of the Vanguard IEP Peripheral Balloon Angioplasty System with Integrated Embolic Protection. The Vanguard IEP Peripheral Balloon Angioplasty System with Integrated Embolic Protection is indicated for peripheral vascular percutaneous transluminal angioplasty (PTA) and capture and removal of embolic material during angioplasty for the femoral, iliac, popliteal and profunda arteries.

The Vanguard System has been designed to revascularize iliac and femoro-popliteal PAD while protecting against embolization at the same time. It is the first system in which the embolic protection filter is coupled on the same catheter as the angioplasty balloon for use in the lower extremities. Up to 130 patients will be enrolled into this study and followed for 30 days after post-procedure. Adult patients with lifestyle-limiting claudication or rest pain (Rutherford categories 2 to 3) who meet all eligibility criteria will be approached for participation in the trial.


Recruitment information / eligibility

Status Completed
Enrollment 113
Est. completion date December 30, 2018
Est. primary completion date November 30, 2018
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

1. Male and female patients =18 years old.

2. Subject has clinically significant symptomatic leg ischemia requiring treatment.

3. Subject has a Rutherford category of 2 - 3.

4. Target lesion in the superficial femoral artery (SFA), common femoral artery, p1 segment of popliteal artery, common iliac artery and external iliac artery (cross-over access only), and profunda femoris arteries.

5. Target lesion stenosis >50% by investigator's visual estimate.

6. Vessel diameter between 4.0 mm and 8.0 mm at the site of the target lesion.

7. Total target lesion length = 18 cm, and may include a chronic total occlusion = 10 cm.

8. If target lesion is restenotic, the prior PTA must be > 30 days prior to enrollment.

9. If the guide wire traverses the lesion subintimally, it must enter the true lumen distal to the lesion without the use of a reentry device.

10. Distal vessel diameter at the site of filter deployment of 4.0 mm to 8.0 mm with sufficient landing zone required for the successful deployment of the integrated embolic protection filter.

11. Patent popliteal and infrapopliteal arteries; I.e. single vessel runoff or better with at least one of three vessels patient (<50% stenosis) to the ankle or foot.

12. The patient (or legally authorized representative) is willing to provide written informed consent and to comply with all study requirements.

Exclusion Criteria:

1. Subjects who have undergone prior vascular surgery of the target artery to treat atherosclerotic disease.

2. History of major amputation in the same limb as the target lesion.

3. Woman who is pregnant or nursing.

4. Subject has Rutherford category of 4- 6.

5. Target lesion(s) within native or synthetic vessel grafts.

6. Use of atherectomy as an adjunctive therapy during the index procedure in the target lesion or target vessel.

7. Any major (e.g. cardiac, peripheral, abdominal) intervention, including in the contralateral lim planned within 30 days post index procedure.

8. Presence of other hemodynamically significant outflow lesion in the target limb requiring intervention within 30 days of enrollment.

9. Subject has significant inflow disease which cannot be treated prior to target lesion treatment.

10. Presence of aneurysm in the target vessel.

11. Acute limb occlusion due to thrombotic occlusion of the target limb.

12. In-stent restenosis of target lesion.

13. Severe calcification that renders the target lesion lesion resistant to angioplasty.

14. Visible acute thrombus in the target lesion

15. Intolerance to antiplatelet, anticoagulant or thrombolytic therapy medications that would be administered during the trial.

16. Known hypersensitivity to contrast media that cannot be adequately premedicated.

17. Known hypersensitivity to nickel and/or titanium.

18. Acute Myocardial Infarction within 30 days prior to the index procedure.

19. Subject has a known coagulopathy or bleeding diathesis, or INR <1.5.

20. Platelet count <100,000 mm3/L or >700,000 mm3/L

21. Concomitant renal failure with a serum creatinine > 2.5 mg/dL or receiving dialysis.

22. Patient is currently participating in an interventional study, investigational drug or device study that has not completed the primary endpoint, that may potentially confound the results of this trial or that would limit the subject's compliance with the follow-up requirements.

Study Design


Related Conditions & MeSH terms


Intervention

Device:
peripheral balloon angioplasty
Percutaneous transluminal angioplasty (PTA) of the lower extremities

Locations

Country Name City State
Belgium OLV Hospital Aalst Aalst
Belgium Imelda Hospital / Vascular Science Research Center Bonheiden
Belgium AZ Sint Blasius Dendermonde
Belgium RZ Heilig Hart Hospital Tienen
Germany Interventional Cardiology and Vascular Medicine, Department of Angiology, Universitäts-Herzzentrum Freiburg Bad Krozingen
Germany Sankt Gertrauden-Krankenhaus Berlin
Germany Daikonissenkrankenhaus Flensburg Flensburg
Germany MVZ/Prof. Mathey Prof. Schofer Clinic Hamburg
Germany Universitätsklinikum Leipzig Leipzig

Sponsors (1)

Lead Sponsor Collaborator
Contego Medical, LLC

Countries where clinical trial is conducted

Belgium,  Germany, 

Outcome

Type Measure Description Time frame Safety issue
Other Histomorphometric analysis of embolic protection filter content Histomorphometric analysis of embolic protection filter content Day 0. Filter collected at end of index procedure.
Primary Freedom from MAE, defined as death, amputation and target vessel revascularization (TVR) Primary safety endpoint 30 days
Primary Procedural success Defined as <50% residual stenosis without MAE (death, amputation or TVR) 24 hours or at discharge.
Secondary Technical Success Technical success of the investigational device using questionnaire Index procedure
Secondary Ankle-Brachial Index (ABI) Change in Ankle-Brachial Index from baseline, discharge and 30 days Baseline, discharge and 30 days
Secondary Rutherford-Becker Rutherford-Becker improvement greater than or equal to 1 30 days
See also
  Status Clinical Trial Phase
Recruiting NCT06032065 - Sequential Multiple Assessment Randomized Trial of Exercise for PAD: SMART Exercise for PAD (SMART PAD) Phase 3
Active, not recruiting NCT03987061 - MOTIV Bioresorbable Scaffold in BTK Artery Disease N/A
Recruiting NCT03506633 - Impacts of Mitochondrial-targeted Antioxidant on Peripheral Artery Disease Patients N/A
Active, not recruiting NCT03506646 - Dietary Nitrate Supplementation and Thermoregulation N/A
Active, not recruiting NCT04677725 - NEtwork to Control ATherothrombosis (NEAT Registry)
Recruiting NCT05961943 - RESPONSE-2-PAD to Reduce Sedentary Time in Peripheral Arterial Disease Patients N/A
Recruiting NCT06047002 - Personalised Antiplatelet Therapy for Patients With Symptomatic Peripheral Arterial Disease
Completed NCT03185052 - Feasibility of Outpatient Care After Manual Compression in Patients Treated for Peripheral Arterial Disease by Endovascular Technique With 5F Sheath Femoral Approach N/A
Recruiting NCT05992896 - A Study of Loco-Regional Liposomal Bupivacaine Injection Phase 4
Completed NCT04635501 - AbsorbaSeal (ABS 5.6.7) Vascular Closure Device Trial N/A
Recruiting NCT04584632 - The Efemoral Vascular Scaffold System (EVSS) for the Treatment of Patients With Symptomatic Peripheral Vascular Disease From Stenosis or Occlusion of the Femoropopliteal Artery N/A
Withdrawn NCT03994185 - The Merit WRAPSODY™ Endovascular Stent Graft for Treatment of Iliac Artery Occlusive Disease N/A
Withdrawn NCT03538392 - Serranator® Alto Post Market Clinical Follow Up (PMCF) Study
Recruiting NCT02915796 - Autologous CD133(+) Cells as an Adjuvant to Below the Knee Percutaneous Transluminal Angioplasty Phase 1
Active, not recruiting NCT02900924 - Observational Study to Evaluate the BioMimics 3D Stent System: MIMICS-3D
Completed NCT02901847 - To Evaluate the Introduction of a Public Health Approach to Peripheral Arterial Disease (PAD) Using National Centre for Sport and Exercise Medicine Facilities. N/A
Withdrawn NCT02126540 - Trial of Pantheris System, an Atherectomy Device That Provides Imaging While Removing Plaque in Lower Extremity Arteries N/A
Not yet recruiting NCT02387450 - Reduced Cardiovascular Morbi-mortality by Sildenafil in Patients With Arterial Claudication Phase 2/Phase 3
Not yet recruiting NCT02455726 - Magnesium Oral Supplementation to Reduce Pain Inpatients With Severe Peripheral Arterial Occlusive Disease N/A
Completed NCT02022423 - Physical Activity Daily - An Internet-Based Walking Program for Patients With Peripheral Arterial Disease N/A